Showing 957 results
-
Press release /Acquisition underscores Novartis commitment to using optogenetics-based therapies to restore vision to patients with advanced blindness Novartis gains one pre-clinical optogenetic AAV gene therapy…
-
Press release /Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1 Subgroup analyses of the EXPAND trial showed the…
-
Press release /Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference medicine Humira®*HCF formulation adalimumab offers…
-
Press release /Basel, December 21, 2018 - Novartis today announced that the European Commission (EC) approved an expanded indication for Kisqali® (ribociclib), the CDK4/6 inhibitor with the largest body of…
-
Press release /Pemetrexed is indicated for patients with non-squamous Non-Small Cell Lung Cancer (NSCLC), who represent over 3 in 4 patients with lung cancer1 New ready-to-dilute format and 1,000 mg strength…
-
Press release /Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of…
-
Press release /Biologics License Application (BLA) is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc. Trastuzumab is monoclonal…
-
Press release /New ALITHIOS data show mean immunoglobulin G (IgG) levels in people treated with Kesimpta remained unchanged over 3.5 years and mean immunoglobulin M (IgM) levels remained within the reference range1…
-
Ad hoc release /Hausse du chiffre d’affaires net des activités poursuivies1 de 9% sur l’exercice entier (tcc2, +6% USD): Pharmaceuticals: cette unité opérationnelle progresse de 12% (tcc), sous l’impulsion de…
-
Press release /Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also…